United States Patent 7,700,550 (Method Claims): Scope, Claim-by-Claim Coverage, and US Patent Estate for Bacterial and Staphylococcal Infections

Executive summary: US Patent 7,700,550 is a US method-of-treatment patent that claims administering a specific defined compound (and pharmaceutically acceptable salts) to humans with bacterial infections, with narrower dependent claim limits for hydrochloride salt, intravenous dosing, once-daily administration, and staphylococcal infection including MRSA and Staphylococcus aureus. The practical enforceability hinge is the patent’s compound-definition text in the specification/drawing, because all method claims are defined by “administering a compound of the formula,” and design-arounds and generic risk will depend on whether the competitor’s API matches that formula or its salts.

What does US Patent 7,700,550 claim cover and what is the effective enforcement scope?

Answer: Claim 1 and claim 5 create a two-tier method-of-use barrier in the US: treating (i) a bacterial infection and (ii) a staphylococcal infection by administering the patented formula compound (or a pharmaceutically acceptable salt) to a human. Dependent claims then limit use by salt identity (HCl salt), route (IV), frequency (once per day), and (for staphylococci) species and MRSA status.

Claim set structure and how infringement is typically measured

US method patents like 7,700,550 usually test infringement in the US by:

Product-to-method mapping: does the accused product deliver the same claimed compound (or an equivalent pharmaceutically acceptable salt)?
Patient population match: is the patient being treated for the claimed infection type (bacterial or staphylococcal, and if applicable MRSA)?
Administration conditions: does the regimen match IV and once-daily for the dependent claims, and hydrochloride salt for the salt-dependent claims?

Key claim dependencies from the text you provided

Below is a direct scope read from the claim language:

Independent claims

Claim 1: Method for treating a bacterial infection in a human by administering a compound of the formula (or pharmaceutically acceptable salt).
Claim 5: Method for treating a staphylococcal infection in a human by administering the compound of the formula (or pharmaceutically acceptable salt).

Dependent claims limiting scope

Claim 2: compound is a hydrochloride salt.
Claim 3: compound or salt is administered intravenously.
Claim 4: compound or salt is administered once per day.
Claim 6: compound is a hydrochloride salt (for claim 5’s staphylococcal use).
Claim 7: administered intravenously (for staphylococcal use).
Claim 8: administered once per day (for staphylococcal use).
Claim 9: staphylococcal infection caused by Staphylococcus aureus.
Claim 10: staphylococcal infection caused by methicillin-resistant Staphylococcus aureus (MRSA).

Practical consequence: the “formula” definition is the pivot

You provided the claims but not the formula structure. That means the enforcement-relevant question is not “is it an antibiotic” but whether the accused compound matches the defined structural scope in the formula.

In practice:

If a competitor markets a regimen with a different active ingredient that is not within the “compound of the formula,” claims 1 and 5 do not read.
If the competitor uses a prodrug, polymorph, or different salt form, the salt and claim construction become central. The dependent claims specifically cover hydrochloride salt, but independent claims already cover “pharmaceutically acceptable salt thereof,” which can broaden coverage to other salts depending on the specification’s view of what salts are “pharmaceutically acceptable.”

How broad are the “bacterial infection” vs “staphylococcal infection” method claims?

Answer: Claim 1 is broader because it covers any bacterial infection. Claim 5 is narrower by infection class (staphylococcal), then further narrowed by dependent claims to S. aureus and MRSA.

Claim 1: “bacterial infection” scope risk for generic entrants

Claim 1 covers treating any bacterial infection in a human with the claimed compound.
This broad language increases the chance that real-world off-label use could fall within the claim, depending on claim construction and evidence of intended use.

Claim 5: staphylococcal infection scope and MRSA specificity

Claim 5 is restricted to staphylococcal infections and therefore is more defensible on indication and clinical labeling alignment.
Dependent claims 9 and 10 specify S. aureus and MRSA, which typically match high-interest hospital indications and resistances that drive patent value.

Which aspects of the regimen are claimed: salt form, route, frequency, and patient infection type?

Answer: The patent claims both what is administered (compound of the formula or pharmaceutically acceptable salt) and in dependent claims how it is administered (hydrochloride salt, intravenous, once per day) and, for staphylococci, which pathogen/resistance profile.

Hydrochloride salt limitation (claims 2 and 6)

Claim 2 narrows claim 1’s compound to the hydrochloride salt.
Claim 6 narrows claim 5’s compound to the hydrochloride salt. Key implications:
If a competitor’s API is a different salt (e.g., acetate, sulfate), dependent claims 2/6 are avoided, but independent claims 1/5 may still be implicated if the salt qualifies as “pharmaceutically acceptable salt” and falls under the specification’s definition.

Intravenous administration limitation (claims 3 and 7)

Claim 3 narrows to intravenous dosing.
Claim 7 narrows staphylococcal use to intravenous dosing. If a product is administered via oral route in the accused regimen, then dependent claims 3/7 are avoided, while claim 1/5 still depend on how “method” is construed vis-a-vis administration route. Courts often require route matching only for dependent claim infringements.

Once per day limitation (claims 4 and 8)

Claim 4 constrains dosing frequency to once per day.
Claim 8 constrains dosing frequency to once per day for staphylococcal infection. If an accused regimen uses different frequency (twice daily, continuous infusion with variable rate), dependent claims 4/8 are not met.

Staphylococcus specificity (claims 9 and 10)

Claim 9: staphylococcal infection caused by S. aureus.
Claim 10: staphylococcal infection caused by MRSA. These are strong hooks for litigation because they align with diagnostic confirmation and stewardship protocols. Generic and biosimilar risk often tracks to these narrower dependent claims when the independent claims are harder to prove due to broader “bacterial infection” dispute.

What design-around strategies are suggested by the claim structure?

Answer: The claim dependencies point to four typical design-around axes: (1) avoid the defined formula compound, (2) avoid hydrochloride salt if independent claims are difficult to attack, (3) avoid IV or once-daily regimen matching, and (4) avoid MRSA-labeled use if the case is being pursued on dependent claims 9/10.

1) Active-ingredient design-around (best protection)

If the competitor’s API is not within the “compound of the formula,” it avoids claims 1 and 5 at the threshold.

2) Salt selection (selective design-around)

Avoiding hydrochloride can potentially avoid dependent claims 2/6, but not necessarily independent claims 1/5 because those already cover “pharmaceutically acceptable salts.”

3) Route and frequency (route-specific and regimen-specific risk)

Switching from IV to an oral route, or altering from once-daily to different dosing frequency, can avoid dependent claims 3/4 and 7/8 while still leaving open possible challenges under claims 1/5 depending on claim construction and the evidentiary record.

4) Indication steering (infection-type specific)

If litigation is framed on dependent staphylococcal claims 9/10, competitors can reduce exposure by avoiding use in MRSA-confirmed indications. That is not a perfect defense against claim 5 but can narrow infringement proof and damages narratives.

How strong is the US method patent estate around US 7,700,550?

Answer: A strength assessment cannot be completed to the level required for litigation or investment without the patent’s specification, prosecution history, claim construction record, and the surrounding family members (continuations, continuations-in-part, related composition-of-matter or formulation patents, and licensing outcomes). Your prompt includes the claim text but not the “compound of the formula” definition, nor any bibliographic data for 7,700,550 or related patents.

No additional patent landscape analysis can be generated while meeting the requirement for accuracy.

What patents typically cover the same drug for composition, formulation, and manufacturing, and how do they interact with 7,700,550?

Answer: In bacterial infection programs, method-of-use patents like 7,700,550 often coexist with:

composition-of-matter patents (API and/or salts),
polymorph/formulation patents (solid-state forms, lyophilized IV dosage forms),
dosing regimen patents (frequency/route),
and method-of-manufacture patents (process constraints).

But the presence, numbering, jurisdiction, and scope of those other patents cannot be determined from the provided information.

What is the regulatory and exclusivity exposure tied to the claimed methods?

Answer: The regulatory path determines whether clinical regimens align with claims. However, without identifying:

the drug name linked to the “compound of the formula,”
the NDA/ANDA/BLA number,
listed patents in the Orange Book (if any),
and any method-of-use listings and expiration dates, a complete regulatory and exclusivity timeline cannot be produced.

No complete and accurate answer can be made from the information provided.

When does US 7,700,550 lose exclusivity: patent expiration and potential terminal disclaimer effects?

Answer: Patent expiration depends on application filing date, claims priority, any PTA, and terminal disclaimer status. Those facts are not present in your prompt, so a precise expiration date cannot be stated.

What Paragraph IV or Hatch-Waxman entry risks exist for a method-of-use patent like 7,700,550?

Answer: If 7,700,550 is listed in the Orange Book as covering a method of using an approved drug product, an ANDA filer can attempt a Paragraph IV challenge to the patent. The practical risk depends on:

whether the method patent is listed for the NDA/strength/form,
whether the ANDA product is used in the patented regimen,
and how courts construe “administering” and proof of use.

No Orange Book listing status can be asserted from the provided information.

What litigation outcomes or settlements typically matter for 7,700,550-style claims?

Answer: For method-of-use patents, litigation often turns on:

infringement evidence: clinical use, label or off-label prescribing, and dosing verification;
claim construction: whether the accused compound matches the “formula” scope and salt identity;
invalidity defenses: obviousness, anticipation, enablement, written description.

No case-specific litigation dossier can be produced without docket references and the patent’s prosecution and asserted prior art.

Key takeaways

US Patent 7,700,550 claims methods of treating bacterial and staphylococcal infections by administering a specific formula compound (or pharmaceutically acceptable salt).
The enforceable claim perimeter is driven by the compound-of-the-formula definition in the patent (not provided here).
Dependent claims create narrower regimen hooks: hydrochloride salt, intravenous dosing, once-daily dosing, and staphylococcal causation including S. aureus and MRSA.
Design-around is most viable by avoiding the defined compound; secondary levers are avoiding hydrochloride and non-matching route/frequency/indication to reduce proof of infringement on dependent claims.
A complete patent estate, exclusivity timeline, Orange Book status, and litigation-ready landscape cannot be generated accurately from the claim text alone.

FAQs

1) Does US 7,700,550 cover oral dosing if the claims recite intravenous?
Dependent claims 3 and 7 require IV. Independent claims do not state a route, but infringement still depends on claim construction and how courts treat “administering” without an explicit route in claims 1 and 5.

2) Can a competitor avoid claim 2 by using a different salt form?
Using a non-hydrochloride salt can avoid dependent claim 2, but independent claims 1 and 5 may still apply if the alternative salt is a “pharmaceutically acceptable salt” within the claim scope.

3) Is MRSA-specific language in claim 10 a separate patentable method or a narrower use?
It narrows claim 5’s staphylococcal treatment to MRSA-caused infections via dependent claim 10.

4) What factual evidence is most important in proving infringement of once-daily dosing claims 4 and 8?
Dosing regimen evidence showing once-per-day administration in humans for the claimed infection type and with the claimed compound.

5) How do claim 1 and claim 5 differ in infringement proof complexity?
Claim 1 is broader (“bacterial infection”) and can raise dispute over infection classification and medical context; claim 5 is narrower (staphylococcal) and can be anchored to culture-confirmed organisms, especially with claims 9/10.

References

No sources can be cited from the information provided.

Title:	Glycopeptide phosphonate derivatives
Abstract:	Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.
Inventor(s):	Michael R. Leadbetter
Assignee:	Cumberland Pharmaceuticals Inc
Application Number:	US11/977,429
Patent Claim Types: see list of patent claims	Use; Delivery;
Patent landscape, scope, and claims:	United States Patent 7,700,550 (Method Claims): Scope, Claim-by-Claim Coverage, and US Patent Estate for Bacterial and Staphylococcal Infections Executive summary: US Patent 7,700,550 is a US method-of-treatment patent that claims administering a specific defined compound (and pharmaceutically acceptable salts) to humans with bacterial infections, with narrower dependent claim limits for hydrochloride salt, intravenous dosing, once-daily administration, and staphylococcal infection including MRSA and Staphylococcus aureus. The practical enforceability hinge is the patent’s compound-definition text in the specification/drawing, because all method claims are defined by “administering a compound of the formula,” and design-arounds and generic risk will depend on whether the competitor’s API matches that formula or its salts. What does US Patent 7,700,550 claim cover and what is the effective enforcement scope? Answer: Claim 1 and claim 5 create a two-tier method-of-use barrier in the US: treating (i) a bacterial infection and (ii) a staphylococcal infection by administering the patented formula compound (or a pharmaceutically acceptable salt) to a human. Dependent claims then limit use by salt identity (HCl salt), route (IV), frequency (once per day), and (for staphylococci) species and MRSA status. Claim set structure and how infringement is typically measured US method patents like 7,700,550 usually test infringement in the US by: Product-to-method mapping: does the accused product deliver the same claimed compound (or an equivalent pharmaceutically acceptable salt)? Patient population match: is the patient being treated for the claimed infection type (bacterial or staphylococcal, and if applicable MRSA)? Administration conditions: does the regimen match IV and once-daily for the dependent claims, and hydrochloride salt for the salt-dependent claims? Key claim dependencies from the text you provided Below is a direct scope read from the claim language: Independent claims Claim 1: Method for treating a bacterial infection in a human by administering a compound of the formula (or pharmaceutically acceptable salt). Claim 5: Method for treating a staphylococcal infection in a human by administering the compound of the formula (or pharmaceutically acceptable salt). Dependent claims limiting scope Claim 2: compound is a hydrochloride salt. Claim 3: compound or salt is administered intravenously. Claim 4: compound or salt is administered once per day. Claim 6: compound is a hydrochloride salt (for claim 5’s staphylococcal use). Claim 7: administered intravenously (for staphylococcal use). Claim 8: administered once per day (for staphylococcal use). Claim 9: staphylococcal infection caused by Staphylococcus aureus. Claim 10: staphylococcal infection caused by methicillin-resistant Staphylococcus aureus (MRSA). Practical consequence: the “formula” definition is the pivot You provided the claims but not the formula structure. That means the enforcement-relevant question is not “is it an antibiotic” but whether the accused compound matches the defined structural scope in the formula. In practice: If a competitor markets a regimen with a different active ingredient that is not within the “compound of the formula,” claims 1 and 5 do not read. If the competitor uses a prodrug, polymorph, or different salt form, the salt and claim construction become central. The dependent claims specifically cover hydrochloride salt, but independent claims already cover “pharmaceutically acceptable salt thereof,” which can broaden coverage to other salts depending on the specification’s view of what salts are “pharmaceutically acceptable.” How broad are the “bacterial infection” vs “staphylococcal infection” method claims? Answer: Claim 1 is broader because it covers any bacterial infection. Claim 5 is narrower by infection class (staphylococcal), then further narrowed by dependent claims to S. aureus and MRSA. Claim 1: “bacterial infection” scope risk for generic entrants Claim 1 covers treating any bacterial infection in a human with the claimed compound. This broad language increases the chance that real-world off-label use could fall within the claim, depending on claim construction and evidence of intended use. Claim 5: staphylococcal infection scope and MRSA specificity Claim 5 is restricted to staphylococcal infections and therefore is more defensible on indication and clinical labeling alignment. Dependent claims 9 and 10 specify S. aureus and MRSA, which typically match high-interest hospital indications and resistances that drive patent value. Which aspects of the regimen are claimed: salt form, route, frequency, and patient infection type? Answer: The patent claims both what is administered (compound of the formula or pharmaceutically acceptable salt) and in dependent claims how it is administered (hydrochloride salt, intravenous, once per day) and, for staphylococci, which pathogen/resistance profile. Hydrochloride salt limitation (claims 2 and 6) Claim 2 narrows claim 1’s compound to the hydrochloride salt. Claim 6 narrows claim 5’s compound to the hydrochloride salt. Key implications: If a competitor’s API is a different salt (e.g., acetate, sulfate), dependent claims 2/6 are avoided, but independent claims 1/5 may still be implicated if the salt qualifies as “pharmaceutically acceptable salt” and falls under the specification’s definition. Intravenous administration limitation (claims 3 and 7) Claim 3 narrows to intravenous dosing. Claim 7 narrows staphylococcal use to intravenous dosing. If a product is administered via oral route in the accused regimen, then dependent claims 3/7 are avoided, while claim 1/5 still depend on how “method” is construed vis-a-vis administration route. Courts often require route matching only for dependent claim infringements. Once per day limitation (claims 4 and 8) Claim 4 constrains dosing frequency to once per day. Claim 8 constrains dosing frequency to once per day for staphylococcal infection. If an accused regimen uses different frequency (twice daily, continuous infusion with variable rate), dependent claims 4/8 are not met. Staphylococcus specificity (claims 9 and 10) Claim 9: staphylococcal infection caused by S. aureus. Claim 10: staphylococcal infection caused by MRSA. These are strong hooks for litigation because they align with diagnostic confirmation and stewardship protocols. Generic and biosimilar risk often tracks to these narrower dependent claims when the independent claims are harder to prove due to broader “bacterial infection” dispute. What design-around strategies are suggested by the claim structure? Answer: The claim dependencies point to four typical design-around axes: (1) avoid the defined formula compound, (2) avoid hydrochloride salt if independent claims are difficult to attack, (3) avoid IV or once-daily regimen matching, and (4) avoid MRSA-labeled use if the case is being pursued on dependent claims 9/10. 1) Active-ingredient design-around (best protection) If the competitor’s API is not within the “compound of the formula,” it avoids claims 1 and 5 at the threshold. 2) Salt selection (selective design-around) Avoiding hydrochloride can potentially avoid dependent claims 2/6, but not necessarily independent claims 1/5 because those already cover “pharmaceutically acceptable salts.” 3) Route and frequency (route-specific and regimen-specific risk) Switching from IV to an oral route, or altering from once-daily to different dosing frequency, can avoid dependent claims 3/4 and 7/8 while still leaving open possible challenges under claims 1/5 depending on claim construction and the evidentiary record. 4) Indication steering (infection-type specific) If litigation is framed on dependent staphylococcal claims 9/10, competitors can reduce exposure by avoiding use in MRSA-confirmed indications. That is not a perfect defense against claim 5 but can narrow infringement proof and damages narratives. How strong is the US method patent estate around US 7,700,550? Answer: A strength assessment cannot be completed to the level required for litigation or investment without the patent’s specification, prosecution history, claim construction record, and the surrounding family members (continuations, continuations-in-part, related composition-of-matter or formulation patents, and licensing outcomes). Your prompt includes the claim text but not the “compound of the formula” definition, nor any bibliographic data for 7,700,550 or related patents. No additional patent landscape analysis can be generated while meeting the requirement for accuracy. What patents typically cover the same drug for composition, formulation, and manufacturing, and how do they interact with 7,700,550? Answer: In bacterial infection programs, method-of-use patents like 7,700,550 often coexist with: composition-of-matter patents (API and/or salts), polymorph/formulation patents (solid-state forms, lyophilized IV dosage forms), dosing regimen patents (frequency/route), and method-of-manufacture patents (process constraints). But the presence, numbering, jurisdiction, and scope of those other patents cannot be determined from the provided information. What is the regulatory and exclusivity exposure tied to the claimed methods? Answer: The regulatory path determines whether clinical regimens align with claims. However, without identifying: the drug name linked to the “compound of the formula,” the NDA/ANDA/BLA number, listed patents in the Orange Book (if any), and any method-of-use listings and expiration dates, a complete regulatory and exclusivity timeline cannot be produced. No complete and accurate answer can be made from the information provided. When does US 7,700,550 lose exclusivity: patent expiration and potential terminal disclaimer effects? Answer: Patent expiration depends on application filing date, claims priority, any PTA, and terminal disclaimer status. Those facts are not present in your prompt, so a precise expiration date cannot be stated. What Paragraph IV or Hatch-Waxman entry risks exist for a method-of-use patent like 7,700,550? Answer: If 7,700,550 is listed in the Orange Book as covering a method of using an approved drug product, an ANDA filer can attempt a Paragraph IV challenge to the patent. The practical risk depends on: whether the method patent is listed for the NDA/strength/form, whether the ANDA product is used in the patented regimen, and how courts construe “administering” and proof of use. No Orange Book listing status can be asserted from the provided information. What litigation outcomes or settlements typically matter for 7,700,550-style claims? Answer: For method-of-use patents, litigation often turns on: infringement evidence: clinical use, label or off-label prescribing, and dosing verification; claim construction: whether the accused compound matches the “formula” scope and salt identity; invalidity defenses: obviousness, anticipation, enablement, written description. No case-specific litigation dossier can be produced without docket references and the patent’s prosecution and asserted prior art. Key takeaways US Patent 7,700,550 claims methods of treating bacterial and staphylococcal infections by administering a specific formula compound (or pharmaceutically acceptable salt). The enforceable claim perimeter is driven by the compound-of-the-formula definition in the patent (not provided here). Dependent claims create narrower regimen hooks: hydrochloride salt, intravenous dosing, once-daily dosing, and staphylococcal causation including S. aureus and MRSA. Design-around is most viable by avoiding the defined compound; secondary levers are avoiding hydrochloride and non-matching route/frequency/indication to reduce proof of infringement on dependent claims. A complete patent estate, exclusivity timeline, Orange Book status, and litigation-ready landscape cannot be generated accurately from the claim text alone. FAQs 1) Does US 7,700,550 cover oral dosing if the claims recite intravenous? Dependent claims 3 and 7 require IV. Independent claims do not state a route, but infringement still depends on claim construction and how courts treat “administering” without an explicit route in claims 1 and 5. 2) Can a competitor avoid claim 2 by using a different salt form? Using a non-hydrochloride salt can avoid dependent claim 2, but independent claims 1 and 5 may still apply if the alternative salt is a “pharmaceutically acceptable salt” within the claim scope. 3) Is MRSA-specific language in claim 10 a separate patentable method or a narrower use? It narrows claim 5’s staphylococcal treatment to MRSA-caused infections via dependent claim 10. 4) What factual evidence is most important in proving infringement of once-daily dosing claims 4 and 8? Dosing regimen evidence showing once-per-day administration in humans for the claimed infection type and with the claimed compound. 5) How do claim 1 and claim 5 differ in infringement proof complexity? Claim 1 is broader (“bacterial infection”) and can raise dispute over infection classification and medical context; claim 5 is narrower (staphylococcal) and can be anchored to culture-confirmed organisms, especially with claims 9/10. References No sources can be cited from the information provided. More… ↓ ⤷ Start Trial

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1292612	⤷ Start Trial	C300507	Netherlands	⤷ Start Trial
European Patent Office	1292612	⤷ Start Trial	CA 2011 00033	Denmark	⤷ Start Trial
European Patent Office	1292612	⤷ Start Trial	91908	Luxembourg	⤷ Start Trial
European Patent Office	1292612	⤷ Start Trial	PA2012002	Lithuania	⤷ Start Trial
European Patent Office	1292612	⤷ Start Trial	1190036-2	Sweden	⤷ Start Trial
European Patent Office	1292612	⤷ Start Trial	11C0051	France	⤷ Start Trial
European Patent Office	1292612	⤷ Start Trial	PA2012002,C1292612	Lithuania	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,700,550

Summary for Patent: 7,700,550